Xilio Therapeutics (XLO) Non-Current Assets (2020 - 2026)

Xilio Therapeutics has disclosed Non-Current Assets across 7 years of filings, most recently posting $9.3 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $9.3 million, down 11.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.6 million (down 13.31% YoY), and the FY2025 annual result was $9.7 million, down 10.91% from the prior year.
• Non-Current Assets came in at $9.3 million for Q1 2026 at Xilio Therapeutics, down from $9.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $15.3 million in Q1 2022 to a low of $9.3 million in Q1 2026.
• The 5-year median for Non-Current Assets is $12.8 million (2023), against an average of $12.4 million.
• Across the five-year window, Non-Current Assets decreased 0.35% in 2022 and fell 21.66% in 2025, its largest moves.
• Xilio Therapeutics' Non-Current Assets stood at $14.7 million in 2022, then retreated by 12.75% to $12.8 million in 2023, then fell by 15.3% to $10.8 million in 2024, then retreated by 10.91% to $9.7 million in 2025, then slipped by 3.91% to $9.3 million in 2026.
• The last three Non-Current Assets figures came in at $9.3 million (Q1 2026), $9.7 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.